Rajdarbar Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 06-07-2024
- Paid Up Capital ₹ 0.60 M
as on 06-07-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2021
- Revenue -46.29%
(FY 2021)
- Profit -111.44%
(FY 2021)
- Ebitda 99.99%
(FY 2021)
- Net Worth -0.08%
(FY 2021)
- Total Assets -55.75%
(FY 2021)
About Rajdarbar Biotech
The Corporate was formerly known as Narsi Value Creations Limited. The Company is engaged in the Consumer Goods Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Prem Jain, Siddhartha Agarwal, and Akhilesh Agarwal serve as directors at the Company.
- CIN/LLPIN
U74120UP2005PLC030180
- Company No.
030180
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Jun 2005
- Date of AGM
22 Sep 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Hathras, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rajdarbar Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prem Jain  | Director | 02-Feb-2021 | Current |
| Siddhartha Agarwal | Director | 16-Jan-2017 | Current |
| Akhilesh Agarwal | Director | 07-Feb-2015 | Current |
Financial Performance and Corporate Structure Insights of Rajdarbar Biotech.
Rajdarbar Biotech Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 46.29% decrease. The company also saw a substantial fall in profitability, with a 111.44% decrease in profit. The company's net worth dipped by a decrease of 0.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rajdarbar Biotech?
In 2018, Rajdarbar Biotech had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rajdarbar Realty Creations Private LimitedActive 29 years 3 monthsAkhilesh Agarwal is a mutual person
- Rajdarbar Iconic Venture Private LimitedActive 33 years 2 months
Akhilesh Agarwal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rajdarbar Biotech?
Unlock and access historical data on people associated with Rajdarbar Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rajdarbar Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rajdarbar Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
